Osoliniec Victor E, Thomas Monique A, de Graaf Robin A, De Feyter Henk M
Magnetic Resonance Research Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT, USA.
Department of Biomedical Engineering, Yale University, New Haven, CT, USA.
Npj Imaging. 2025 Oct 24;3(1):54. doi: 10.1038/s44303-025-00113-y.
Deuterium metabolic imaging (DMI) is a new imaging approach that provides unique, complementary information to anatomical MRI of brain tumors. Preclinical DMI studies have demonstrated excellent image contrast following intravenous infusion of deuterated choline (H-Cho) at a severalfold higher dose than recommended for humans. We investigated DMI performance in rat glioblastoma models after oral administration of a H-Cho dose recommended for humans. DMI, following the three daily oral low doses, resulted in H-Cho concentrations in the tumor and tumor-to-normal-brain image contrast comparable to a single, high intravenous dose. Further, ²H and 2D ¹H-N HSQC NMR on excised tumor tissue revealed that oral administration led to increased contributions from Cho-derived molecules that were products of tumor metabolism compared to intravenous infusion of H-Cho. These results can advance clinical translation of Cho-DMI as a noninvasive imaging tool for brain tumor characterization by demonstrating the feasibility of an oral intake approach using a clinical dose.
氘代谢成像（DMI）是一种新的成像方法，可为脑肿瘤的解剖学磁共振成像提供独特的补充信息。临床前DMI研究表明，静脉输注氘代胆碱（H-Cho）时，剂量比推荐给人类的剂量高出几倍，图像对比度极佳。我们研究了在大鼠胶质母细胞瘤模型中口服推荐给人类剂量的H-Cho后DMI的性能。连续三天口服低剂量后，DMI导致肿瘤中的H-Cho浓度以及肿瘤与正常脑的图像对比度与单次高剂量静脉注射相当。此外，对切除的肿瘤组织进行的²H和二维¹H-N HSQC NMR显示，与静脉输注H-Cho相比，口服给药导致肿瘤代谢产物中Cho衍生分子的贡献增加。这些结果通过证明使用临床剂量口服摄入方法的可行性，可推动Cho-DMI作为一种用于脑肿瘤特征描述的非侵入性成像工具的临床转化。
